We Claim:

1. An isolated peptide consisting essentially of the amino acid sequence: Asn Pro Arg Gly Val Ser Xaa Tyr Xaa Xaa Arg Xaa (SEQ ID NO. 72).
2. The amino acid of claim 1, wherein the amino acid sequence is: Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro (SEQ ID NO. 73).
3. An isolated peptide consisting essentially of the amino acid sequence: Leu Pro Arg Ala Leu Xaa Arg Ser Xaa (SEQ ID NO: 74).
4. The peptide of claim 3, wherein the amino acid sequence is:
    a) Leu Pro Arg Ala Leu Met Arg Ser Thr (SEQ ID NO: 75)
    b) Hi Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr (SEQ ID NO: 76); or
    c) Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr (SEQ ID NO:77).
5. A composition comprising the peptide of claim 1 or claim 3 and a physiologically acceptable carrier, diluent, stabilizer or excipient.
6. The composition of claim 5, further comprising an immunogenic carrier.
7. The composition of claim 6, wherein the immunogenic carrier is selected from the group consisting of BSA, KLH, tetanus toxoid, and diphtheria toxoid.
8. An isolated antibody that specifically binds to the peptide of any one of claims 1 to 4.
9. The antibody of claim 8, further comprising a label.
10. The antibody of claim 8, wherein the antibody is:
    a) a chimeric antibody,
    b) a single chain antibody,
    c) a Fab fragment,
    d) a F(ab'), fragment,
    e) a human antibody, or
    f) a humanized antibody.
11. A composition comprising an antibody of claim 8 and an acceptable carrier.
12. A method preparing a polyclonal antibody, the method comprising:
    a) immunizing an animal with a polypeptide consisting of an amino acid

sequence of SEQ ID NO:72 or SEQ ID NO:74 under conditions to elicit an antibody response,

b) isolating antibodies from the animal, and

c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which specifically binds with high affinity to a polypeptide comprising an amino acid sequence of SEQ ID NO:72 or SEQ ID NO:74.

13. A polyclonal antibody produced by a method of claim 12.

14. A composition comprising the polyclonal antibody of claim 13 and a suitable carrier.

15. A method of making a monoclonal antibody, the method comprising:

a) immunizing an animal with a polypeptide consisting essentially of an amino acid sequence of SEQ ID NO:72 or SEQ ID NO:74 under conditions to elicit an antibody response,

b) isolating antibody producing cells from the animal,

c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells,

d) culturing the hybridoma cells, and

e) isolating from the culture a monoclonal antibody which specifically binds with high affinity to a polypeptide comprising an amino acid sequence of SEQ ID NO:72 or SEQ ID NO:74.

16. A monoclonal antibody produced by a method of claim 15.

17. A composition comprising the monoclonal antibody of claim 16 and a suitable carrier.

18. The antibody of claim 8, wherein the antibody is produced by screening a Fab expression library.

19. The antibody of claim 8, wherein the antibody is produced by screening a combinatorial immunoglobulin library.

20. A kit comprising the antibody of any one of claims 8-19.

21. A method of inducing an immunological response to IgE in a mammal comprising administering the peptide or the composition of any one of claims 1-7, in an amount sufficient to induce a response in said mammal.

We Claim:

1. An isolated antibody or an antigen binding fragment thereof comprising a variable light chain region comprising CDRL1, CDRL2, and CDRL3 and a variable heavy chain region comprising CDRH1, CDRH2, and CDRH3, wherein CDRL1 consists of SEQ ID NO:5, CDRL2 consists of SEQ ID NO:8, CDRL3 consists of the amino acid sequence consisting of QQSWSWPTT, CDRH1 consists of SEQ ID NO:16, CDRH2 consists of SEQ ID NO:20, and CDRH3 consists of SEQ ID NO:26.

2. An isolated antibody or an antigen binding fragment thereof comprising a variable light chain region comprising CDRL1, CDRL2, and CDRL3 and a variable heavy chain region comprising CDRH1, CDRH2, and CDRH3, wherein CDRL1 consists of SEQ ID NO:5, CDRL2 consists of SEQ ID NO:8, CDRL3 consists of QQSWSWPTT, CDRH1 consists of SEQ ID NO:15, CDRH2 consists of SEQ ID NO:25, and CDRH3 consists of SEQ ID NO:26.

3. An isolated antibody or an antigen binding fragment thereof comprising a variable light chain region comprising CDRL1, CDRL2, and CDRL3 and a variable heavy chain region comprising CDRH1, CDRH2, and CDRH3, wherein CDRL1 consists of SEQ ID NO:5, CDRL2 consists of SEQ ID NO:8, CDRL3 consists of QQSWSWPTT, CDRH1 consists of SEQ ID NO:16, CDRH2 consists of SEQ ID NO:24, and CDRH3 consists of SEQ ID NO:26.

4. The antibody or the antigen binding fragment thereof of claim 1, wherein the variable light chain region comprises the amino acid sequence set forth in SEQ ID NO:61 and the variable heavy chain region comprises the amino acid sequence set forth in SEQ ID NO:62.

5. The antibody or the antigen binding fragment thereof of claim 1, wherein the variable light chain region comprises the amino acid sequence set forth in SEQ ID NO:63 and the variable heavy chain region comprises the amino acid sequence set forth in SEQ ID NO:64.

6. The antibody or the antigen binding fragment thereof of claim 1, wherein the variable light chain region comprises the amino acid sequence set forth in SEQ ID NO:65 and the variable heavy chain region comprises the amino acid sequence set forth in SEQ ID NO:66.

7. The antibody or the antigen binding fragment thereof of any one of claims 1-6, wherein the antibody or antigen binding fragment further comprises a constant light chain region and a constant heavy chain region.

8. The antibody or the antigen binding fragment thereof of claim 7, wherein the constant light chain region has the amino acid sequence set forth in SEQ ID NO:58 and the constant heavy chain region has the amino acid sequence set forth in SEQ ID NO:60.

9. A composition comprising a therapeutically effective amount of the antibody of any one of claims 1-6 and a pharmaceutically acceptable carrier.

10. The antibody of any one of claims 1-6, further linked to a label.

11. A diagnostic kit comprising the antibody of any one of claims 1-6.

12. Use of an antibody of any one of claims 1-6 in the manufacture of a medicament for treating of an IgE-mediated disorder, wherein the IgE-mediated disorder is selected from the group consisting of asthma, allergic rhinitis, eczema, urticaria, atopic dermatitis, and a food allergy.

13. An isolated nucleic acid encoding the antibody of claim 1.

14. A vector comprising the isolated nucleic acid of claim 13.

15. An isolated host cell comprising the vector of claim 14.

16. The isolated host cell of claim 15, wherein the cell is ATCC Deposit Number PTA-5678.

17. An isolated nucleic acid encoding the antibody of claim 2.

18. A vector comprising the isolated nucleic acid of claim 17.

19. An isolated host cell comprising the vector of claim 18.

20. The isolated host cell of claim 19, wherein the cell is ATCC Deposit Number PTA-5680.

21. An isolated nucleic acid encoding the antibody of claim 3.

22. A vector comprising the isolated nucleic acid of claim 21.

23. An isolated host cell comprising the vector of claim 22.

24. The isolated host cell of claim 23, wherein the cell is ATCC Deposit Number PTA-5679.

25. A method for producing the antibody of claim 1, comprising culturing the cell of claim 16 under conditions appropriate for the production of said antibody, and isolating the antibody produced.

26. A method for producing the antibody of claim 2, comprising culturing the cell of claim 20 under conditions appropriate for the production of said antibody, and isolating the antibody produced.

27. A method for producing the antibody of claim 3, comprising culturing the cell of claim 24 under conditions appropriate for the production of said antibody, and isolating the antibody produced.